Literature DB >> 7957939

Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein.

A C Simonsen1, C W Heegaard, L K Rasmussen, L Ellgaard, L Kjøller, A Christensen, M Etzerodt, P A Andreasen.   

Abstract

We here report that the M(r) 40,000 receptor associated protein (RAP), previously found to bind to alpha 2-macroglobulin receptor/low density lipoprotein receptor related protein (alpha 2MR/LRP) and glycoprotein 330 (gp330), binds to an M(r) 105,000 membrane protein from bovine mammary gland, human mamma tumors and mammary epithelial cell lines. We have purified this protein from bovine and human sources. N-terminal amino acid sequencing and immunoblotting analyses showed that the protein was identical or closely related to very low density lipoprotein receptor (VLDL-R). Experiments with the human mamma carcinoma cell line MCF-7 showed that this receptor was able to mediate an efficient endocytosis of RAP. These novel findings strongly suggest that RAP functions as a modulator of ligand binding to VLDL-R, similarly to alpha 2MR/LRP and gp330.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957939     DOI: 10.1016/0014-5793(94)01138-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique.

Authors:  V N Bochkov; V A Tkachuk; M P Philippova; D V Stambolsky; F R Bühler; T J Resink
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations.

Authors:  Tao Chen; Fan Wu; Feng-Ming Chen; Jun Tian; Shen Qu
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

3.  Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

Authors:  Bénédicte Chazaud; Rémy Ricoux; Christo Christov; Anne Plonquet; Romain K Gherardi; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

5.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

Authors:  K M Argraves; K F Kozarsky; J T Fallon; P C Harpel; D K Strickland
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry.

Authors:  H A Multhaupt; M E Gåfvels; K Kariko; H Jin; C Arenas-Elliot; B I Goldman; J F Strauss; B Angelin; M J Warhol; K R McCrae
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

7.  Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.

Authors:  M C Jong; K W van Dijk; V E Dahlmans; H Van der Boom; K Kobayashi; K Oka; G Siest; L Chan; M H Hofker; L M Havekes
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

8.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins.

Authors:  Keiko Sakai; Oliver Tiebel; M Cecilia Ljungberg; Merry Sullivan; Hye-Jeong Lee; Tomoya Terashima; Rongying Li; Kunihisa Kobayashi; Hui-Chen Lu; Lawrence Chan; Kazuhiro Oka
Journal:  Brain Res       Date:  2009-04-22       Impact factor: 3.252

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.